CD20 | Jotup

Nutcracker Therapeutics Demonstrates Enhanced Activity of B Cell Lymphoma Candidate NTX-472 at the 2024 ASCO Annual Meeting

Retrieved on:

onsdag, juni 5, 2024

Nutcracker Therapeutics, Inc. , a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, recently presented a poster on NTX-472, its new preclinical drug candidate for B cell lymphoma, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Key Points:

Nutcracker Therapeutics, Inc. , a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, recently presented a poster on NTX-472, its new preclinical drug candidate for B cell lymphoma, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Monoclonal antibody immunotherapies can provide an effective treatment for B cell lymphoma.
Nutcracker Therapeutics’ scientists engineered a panel of molecules simultaneously targeting CD20, CD19 and CD47 to compare them to existing monoclonal antibody immunotherapies for B cell lymphoma, including rituximab (monospecific anti-CD20) and tafasitamab (monospecific anti-CD19).
During SITC 2023, Nutcracker Therapeutics demonstrated similar cytotoxic activity of NTX-471 to existing anti-CD47 molecules, but with little-to-no binding to red blood cells.

Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting

Retrieved on:

fredag, maj 24, 2024

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that five abstracts with Innate’s drug candidates have been accepted for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois.

Key Points:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that five abstracts with Innate’s drug candidates have been accepted for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois.
Abstract Title: Lacutamab in patients with relapsed and/or refractory mycosis fungoides: results from the TELLOMAK Phase 2 trial
Abstract Title: A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients With Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
Abstract Title: Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK Cell Engager directed against CD20 for R/R B-NHL, in comparison to a CD20-targeting T Cell Engager
Abstract Title: A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study.

NeraCare Announces Publication of Abstract on Clinical Validation of a Prognostic 7-Biomarker Assay for Prediction of Relapse in Patients with Early-Stage Cutaneous Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on:

torsdag, maj 23, 2024

Results of the Melarisk-001 study demonstrated that use of 7-IHC identified 98% of relapses and 100% of cutaneous melanoma-related deaths in stage IB/IIA patients.

Key Points:

Results of the Melarisk-001 study demonstrated that use of 7-IHC identified 98% of relapses and 100% of cutaneous melanoma-related deaths in stage IB/IIA patients.
Patients with 7-IHC high-risk had a relapse rate comparable to stage IIB-IV patients for whom adjuvant therapy is approved.
Results of the study suggest its utility in selecting early-stage melanoma patients for adjuvant trials.
Title: Clinical validation of a prognostic 7-marker IHC assay (7-IHC) in 382 patients (pts) with stage IB/IIA cutaneous melanoma (CM; MELARISK-001)

Nutcracker Therapeutics to Unveil New Drug Candidate NTX-472 at ASCO 2024 and Participate in the Sachs Oncology Innovation Forum

Retrieved on:

torsdag, maj 16, 2024

NTX-472 uses engineered mRNA-encoded proteins to simultaneously engage CD20, CD19, and CD47.

Key Points:

NTX-472 uses engineered mRNA-encoded proteins to simultaneously engage CD20, CD19, and CD47.
Nutcracker Therapeutics is currently developing the candidate for the treatment of B cell lymphoma.
Additionally, Dr. Nicole Fay, director of pharmacology and product lead for NTX-250 (the company’s lead candidate), will be presenting and participating in a panel discussion at the 10th Sachs Oncology Innovation Forum (OIF) on May 31, which runs concurrently with the ASCO annual meeting.
Title: Development of NTX-472, a formulated mRNA therapy targeting CD20, CD19, and CD47, for treatment of B-cell lymphoma

Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress

Retrieved on:

onsdag, maj 15, 2024

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate’s drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.

Key Points:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate’s drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.
Two abstracts are related to SAR443579 (IPH6101), an investigational trifunctional anti-CD123 NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi and currently being evaluated as a monotherapy in a Sanofi-sponsored Phase 1/2 clinical trial for the treatment of blood cancers with high unmet needs.
Two abstracts are related to IPH6501, Innate’s second generation ANKET® for the treatment of relapsed or refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma, currently in Phase 1/2 clinical trial.
“We’re pleased to see a continued momentum around our ANKET® platform assets, SAR443579 and IPH6501,” said Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma.

Innate Pharma Reports First Quarter 2024 Business Update and Financial Results

Retrieved on:

tisdag, maj 14, 2024

Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, EV, Drug, Relapse, PDX, MF, FDA, Form, CD20, Carcinoma, Amyloidosis, Euronext Paris, Acute myeloid leukemia, Randomized controlled trial, B-ALL, NK, AACR, Telephone, ADC, Neoplasm, PD-1, ATM, NHL, CRT, Acute lymphoblastic leukemia, GEMOX, Food, NSCLC, EVP, ADS, IPHA, Cancer, ASCO, Poster, BCMA, Oxaliplatin, AstraZeneca, Takeda, Bone marrow, IPH, Lung cancer, Prospectus, PTCL, Spacecraft, CD123, Abstract, Webcast, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2024.

Key Points:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2024.
Top-line results in MF patients will be presented at the ASCO Annual Meeting 2024 being held May 31 – June 4 in Chicago.
Cash, cash equivalents and financial assets of the Company amounted to €113.9 million as of March 31, 2024.
Cash, cash equivalents and financial assets as of March 31, 2024 do not include the €4.0 million payment to be received from Sanofi.

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Retrieved on:

måndag, april 22, 2024

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will present first data exploring novel TALEN® editing processes in hematopoietic stem and progenitor cells (HSPCs) at the American Society of Gene and Cell Therapy (ASGCT) being held on May 7-11, 2024.

Key Points:

“These two posters showcase the potential and versatility of the TALEN® technology to promote efficient gene insertion in HSPCs.
Cellectis has developed a TALEN® mediated promoter-less intron editing technology that enables the expression of a therapeutic transgene exclusively by monocyte derived from edited HSPCs.
This novel editing approach is an important addition to the HSPC gene editing toolbox that might unlock new strategies for the treatment of metabolic and neurological diseases.
Cellectis has developed and optimized a novel gene editing process, leveraging the TALEN® technology and circular single strand DNA template delivery, enabling highly efficient gene insertion in HSPCs.

Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis

Retrieved on:

onsdag, april 17, 2024

AlloNK is a non-genetically modified, allogeneic, cryopreserved NK cell therapy candidate being developed to enhance the activity of B-cell targeting monoclonal antibodies to drive B-cell depletion.

Key Points:

AlloNK is a non-genetically modified, allogeneic, cryopreserved NK cell therapy candidate being developed to enhance the activity of B-cell targeting monoclonal antibodies to drive B-cell depletion.
To our knowledge, this is the first time a patient has received an allogeneic NK cell therapy candidate in a U.S. clinical trial for treatment of an autoimmune disease.
Artiva is collaborating with Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, to support the evaluation of AlloNK for LN.
The Network, overseen by Lupus Therapeutics, is comprised of leading research centers throughout North America with the purpose of accelerating and optimizing lupus clinical trials.

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Retrieved on:

torsdag, mars 28, 2024

WORCESTER, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced its expansion into autoimmune diseases with MB-106, a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”). Mustang and Fred Hutch are in preliminary discussions to explore a potential Phase 1 investigator-sponsored clinical trial to evaluate MB-106 for the treatment of autoimmune diseases.

Key Points:

MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”).
Mustang and Fred Hutch are in preliminary discussions to explore a potential Phase 1 investigator-sponsored clinical trial to evaluate MB-106 for the treatment of autoimmune diseases.
“MB-106’s observed safety profile, encouraging efficacy data, and our robust manufacturing capabilities have the potential to translate to improved outcomes for patients with autoimmune diseases.
Several antibody therapies targeting CD20 on B-cells have successfully transitioned from cancer to autoimmune diseases, such as rituximab for both lymphoma and rheumatoid arthritis.

Hashnote Partners with CoinDesk Indices to Launch the Hashnote CoinDesk 20 Fund, Providing Access to the Leading Digital Asset Class Benchmark

Retrieved on:

tisdag, mars 19, 2024

This collaboration introduces the Hashnote CoinDesk 20 Fund, designed to track the CoinDesk 20 Index (CD20), a highly traded, global digital asset benchmark.

Key Points:

This collaboration introduces the Hashnote CoinDesk 20 Fund, designed to track the CoinDesk 20 Index (CD20), a highly traded, global digital asset benchmark.
*
“Launching the Hashnote CoinDesk 20 Fund marks a pivotal step in providing investors with a regulated avenue to the digital assets market.
Simultaneously, Bullish , the fastest-growing regulated digital asset exchange, launched a new perpetual futures contract based on the CoinDesk 20 Index.
Hashnote will now provide regulated and compliant access to the CoinDesk 20, catering to investors seeking digital asset diversification beyond bitcoin.